Clinical Trials Therapeutics Combination Therapy Repurposing Drugs NSAIDs Natural Compounds FDA Approval Cancer Treatments Clinical Research Drug Repurposing Investigational Drugs ATI2341 Cancer Drugs Alternative Treatments Opioid Receptors Anti-inflammatory Drugs Targeted Therapy Anticancer Drugs Naloxone Enhancement Opioid Overdose Treatment Opioid Withdrawal Research and Development Compound Screening Biological Agents GSM-15606 Hormone Regulation Neurological Diseases Peptide Drugs Cancer Therapies Taste Receptors ABHD6 Inhibitors Cellular Mechanisms Treatment Strategies Steroids Antiviral Agents Targeted Therapies Molecular Design Enzyme Inhibitors Dosage Optimization Small-Molecule Drugs Metabolic Health Nucleoside Reverse Transcriptase Inhibitors Anti-inflammatory Agents Therapeutic Approaches Drug Mechanisms PDE3 Inhibitors Clinical Guidelines Anticoagulants G Protein-Coupled Receptors Ambroxol GLP-1 Receptor Agonists Anticancer Agents Kinase Inhibitors Topical Treatments Biosensors Addiction Treatment Carbohydrate-based Drugs Molecular Targeting Cyclophilin Inhibitors Insecticides Biased Signaling Zileuton Asthma Treatments Antidepressants Seizure Medications Central Nervous System Drugs Small Molecules Antibiotics Cholesterol Drugs ALOX15 Expression KDS12025 Appetite Stimulants Antibody-Drug Conjugates Racetam Class Chagas Disease Treatment Inhaled Medications Gene Therapy Research Initiatives Clinical Phases Natural Remedies Synthetic Drugs Preclinical Research Hormonal Treatments Cannabinoids Aptamer Technology Treatment Options GLP-1 Drugs Therapeutic Strategies Aldosterone Inhibitors Molecular Pharmacology Antifungal Drugs Biologics Experimental Drugs Rapamycin TYK2 Inhibitors Immunosuppressants
Want to see what podcasts are saying about this topic? Search across 145K+ podcasts. Explore Radar
A Nature study points to calming reactive glial cells with targeted anti-inflammatory treatments as a new way to prevent seizure‑causing brain lesions.
